EPCAM and breast cancer: The study revealed a correlation between CTC surface markers like EPCAM+, CD44+, CD47+and MET+ve, with an increase in the number of metastatic sites and reduced survival rates, thus providing data for the development of better diagnostic tools for the treatment of metastatic BC [83].